Several clinical trials have demonstrated the safety and effectiveness of oral tenofovir disoproxil fumarate ( TDF ) , with or without emtricitabine ( FTC ) , as pre-exposure prophylaxis ( PrEP ) for reducing the risk of HIV acquisition .